HAGAR Releases Preliminary Study Results for its Non-Invasive Glucose Monitoring System

HAGAR is touting preliminary data from its clinical study for its non invasive glucose monitoring device, GWave.
 
In contrast to invasive continuous glucose monitors currently available in the market, GWave measures blood glucose as opposed to the interstitial fluid which creates a greater lag time. The accuracy gained by measuring the blood glucose provides both pre-diabetic and diabetic individuals the opportunity to monitor their glucose levels non-invasively, whilst working towards prevention and reduction in overall risk. In addition to its accuracy, the GWave device is a third of the size of a smartphone and contains significantly less radio frequency exposure than the average smartphone. 
 
This current ongoing study with Professor Ami Navon from the Weizmann Institute of Science demonstrates the significant accuracy of GWave’s technology. Participants were tested multiple times on two separate GWave devices using capillary blood as the benchmark. All results fell within the A Zone on the Clarke Error Grid Analysis (EGA). Blood glucose levels ranged from 70-140. The study will focus on continued data collection on higher blood glucose levels. HAGAR plans to conduct two additional studies, one at Schneider Children’s Medical Center of Israel and one led by the esteemed Dr. Roy Beck, founder and director of the Jaeb Center for Health Research (JCHR) in Tampa, Fla.
 
Most recently, HAGAR has partnered with a multinational chip manufacturer specializing in RF to mass-produce its chips. The partnership enables HAGAR to deliver a complete 360-degree product. By bringing in the Taiwanese-based manufacturer, HAGAR’ technology brings a significant breakthrough when it comes to the reproducibility of the device.
 
This year HAGAR welcomed Dr. Moshe Phillip, director of the Institute of Endocrinology at Schneider Children’s Hospital and co-chairman of the International Conference for Advanced Technologies and Treatments of Diabetes (ATTD), as a medical advisor. Dr. Phillip joins HAGAR’s advisory board with such renowned experts as Dr. Alexander Fleming and Dr. Irl Hirsch, who recently was awarded the President’s Innovation Award at ATTD.
 
“Almost 80% of the 463 million adults living with diabetes globally come from low and middle-income countries. This makes the development of a device like GWave even more significant as it enables testing and glucose monitoring to be accessible to more people than ever before,” Hirsch said. “GWave looks to bridge the growing healthcare divide between individuals who can afford sophisticated glucose monitoring devices and those who lack the resources to use them with its own device that allows for a price point at a far more affordable cost than anything currently on the market.”
 
This clinical trial is part of the ongoing efforts of HAGAR to demonstrate the efficacy of its technology is in helping patients manage their health and reduce the risks of long-term complications. In its final form, GWave’s technology will be integrated into a smartwatch, adding to its accessibility and affordability for patients worldwide.
 
The company is completing a Series C funding round and the capital will be allocated towards the upcoming studies planned for Israel and the United States.
 
HAGAR N.I.G. (Non-invasive Glucose monitoring) developed GWave, the first non-invasive continuous glucose monitoring technology that uses RF waves to measure glucose levels in the blood. GWave First Generation is a third of the size of a smartphone that sends glucose readings to the user via a smartphone app that can easily be shared with their healthcare provider.